Brief: MaaT Pharma: Positive Results From Study In Blood Cancer Patients

Maat Pharma SA

02/06/2022 17:04

June 2 (Reuters) - MAAT PHARMA SA  MAAT.PA :
    * MAAT PHARMA CONFIRMS POSITIVE RESULTS FROM COMPLETED PHASE
1B
CIMON STUDY EVALUATING MAAT033 IN BLOOD CANCER PATIENTS
    * COMPLETE TRIAL RESULTS WILL BE SUBMITTED FOR PRESENTATION
AND/OR
PUBLICATION IN A PEER-REVIEWED FORUM
    * COMPANY ON TRACK WITH PREPARATIONS FOR UPCOMING PHASE 2/3
TRIAL
TO EVALUATE MAAT033'S EFFICACY IN IMPROVING OVERALL SURVIVAL
    * MAAT033 PRESENTED A GOOD SAFETY AND TOLERABILITY PROFILE,
EVALUATED AS PRIMARY ENDPOINT
    * TOPLINE RESULTS ALSO SHOW RAPID AND PERSISTENT ENGRAFTMENT
OF
MAAT033 IN PATIENTS' GUT
    * STUDY DATA SUPPORT COMPANY'S PREPARATION TO INITIATE A
PHASE 2/3
TRIAL LATER THIS YEAR

Source text for Eikon:  ID:nBw7ZpLJ8a 
Further company coverage:  MAAT.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 587 696 600;))